Exchange: NASDAQ·Updated 04:12 PM EST
SXTP logo

SXTP 60 Degrees Pharmaceuticals Inc

$0.50
$0.0038
(0.71%)
Today
Closed $0.5379
$0.0379
(7.05%)
After Hours
Reported EarningsAug 14
Mkt Cap$2.4M
Vol33,018.00

About SXTP

60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. Its product Arakoda helps in the prevention of malaria. The company was founded by Geoffrey Dow on September 9, 2010 and is headquartered in Washington, DC.
43

Bearish Sentiment

How do you feel about SXTP?

Hooparena
$SXTP Great results so far. Wasn’t expecting announcements until January but it must be better than expected so they decided to do it earlier. Still need final FDA approval and expect it to happen. At least we have eyes on the stock again and should see positive price action moving forward.
1
RTPRwire
$SXTP is moving on clinical trial results following a Globe Newswire release. 60 Degrees Pharmaceuticals reports all five completed expanded access babesiosis patients showed clinical improvement and negative PCR results with tafenoquine-atovaquone treatment. RTPR pushed this release out to users at 8:06:00 AM ET
1
BreakoutBullz
$SXTP 60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients
1
Tryitin
$SXTP Not a surprise. They have negative cash and fell below 1$ SP and broke below the DTL. Are they heading down for another RS? They have not done RS since Jan 2026.
RTPRwire
Today's biggest catalyst moves on the wire (validated intraday captures through 5:15 PM ET): $SXTP ran as much as +40% — partnership $AIBT ran as much as +39% — product launch $BEAT.X ran as much as +39% — clinical trial results $GMAB ran as much as +33% — clinical trial results $PODC ran as much as +28% — M&A / acquisition Get real-time catalyst alerts using RTPR.
DARKP00L
$SXTP 10:37 on Oct. 28 2026 60 Degrees Pharmaceuticals Announces Partnership with The University of Southern Mississippi to Evaluate Castanospermine in Nonclinical Models of Alpha-Gal Syndrome #tradeideas
RTPRwire
$SXTP is moving on partnership following a Globe Newswire release. 60 Degrees Pharmaceuticals partners with University of Southern Mississippi to evaluate castanospermine for treating alpha-gal syndrome in nonclinical models. RTPR pushed this release out to users at 8:30:01 AM ET
ShodAchiever
$SXTP Shorts NOT underwater BUT spread's wound up so tight that if they cover, it will send the price up like a rocket. Buy! SL 0.58 (Not live though) TP 0.83 Can you hold long enough and scalp all the long as it sells off - go for it. Safe bet! SSR triggered. I am in for the ride considering I will average down at least 4 times and buy and sell all along the way!
Goodstockday
$SXTP This is not a stock I follow closely. This data looks good to me, perfect no, but good enough FDA approval and use. So, every 5th patient needs another round of treatment to get complete clearance, that is just more revenue.
Hooparena
$SXTP In my opinion if FDA gives final approval, the odds of a takeover proposal from Knight Therapeutics seems likely. Knight taking a 20% position in SXTP just a few months ago appears to show the value of this drug has for future usage and monetary value. Playing biotechs is always a patient and stomach churning time but payoff percentages are higher when all goes well. Good luck to all.
Stock_Catcher
$SXTP 60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients
Rayvio_News_Filter
$SXTP 🏥 60 Degrees Pharmaceuticals reported that all five completed expanded access babesiosis study patients had much or very much improved clinical outcomes and negative conventional PCR results, with 80% negative on post-treatment NAT; two patients remain on treatment. Selected from hundreds of headlines

Advertisement|Remove ads.